CN109985051A - The new application of Inonotus obliquus alcohol - Google Patents
The new application of Inonotus obliquus alcohol Download PDFInfo
- Publication number
- CN109985051A CN109985051A CN201711480659.1A CN201711480659A CN109985051A CN 109985051 A CN109985051 A CN 109985051A CN 201711480659 A CN201711480659 A CN 201711480659A CN 109985051 A CN109985051 A CN 109985051A
- Authority
- CN
- China
- Prior art keywords
- formulas
- preparation
- compound
- cataract
- crystalline lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of new applications of Inonotus obliquus alcohol.Specifically, the present invention provides the purposes of compound shown in a kind of Formulas I or its optical isomer or its racemic modification or its solvate or its pharmaceutically acceptable salt or its prodrug, they be used to prepare pharmaceutical composition or preparation, and described pharmaceutical composition or preparation are for preventing and/or treating eye disease caused by crystalline lens lesion.Present invention firstly discovers that compound shown in Formulas I can prevent and/or treat eye disease caused by crystalline lens lesion, such as the prevention and treatment of cataract, and it is highly-safe, toxic side effect is small and has significant therapeutic effect and development and application prospect.
Description
Technical field
The present invention relates to field of medicaments, in particular it relates to a kind of new application of triterpene compound.
Background technique
The crystalline lens of normal eye is made of numerous orderly aligned crystallins, once these crystallins arrange
Mistake accumulation occurs for mistake, will influence the normal transparency of crystalline lens and index of refraction.Wherein, cataract is a kind of main
The form of expression and world wide in the highest disease of blinding.Therefore, the treatment of lens diseases, especially cataract and
Prevention, it is just very important.Regrettably, at present clinically still to perform the operation and replace artificial lens as essential therapeutic arsenals.
How drug is simply utilized, so that it may which prevention even treatment cataract is always the hot spot of ophthalmology research.Have before
Study group reports the cataract that can treat animal using lanosterol, and the structural formula of lanosterol is shown below:
Lanosterol
It is important to note, however, that the lanosterol drug of sustained release only combines high frequency time glass cavity drug administration by injection mode
Meanwhile just there is the therapeutic effect of cataract to dog；Also, there is researcher to also indicate that lanosterol can not restore or to improve caryogram white
The transparency of cataract or glaucoma crystal.
Therefore, this field needs to develop a kind of drug for treating eye disease, to mitigate the pain of patient, improves patient
Quality of life.
Summary of the invention
It is an object of the invention to provide a kind of Inonotus obliquus alcohol effectively treatment crystalline lens lesion or with crystalline lens lesion
Its application of relevant eye disease.
The first aspect of the present invention, provide compound or its optical isomer or its racemic modification shown in a kind of Formulas I or
The purposes of its solvate or its pharmaceutically acceptable salt or its prodrug or its prodrug, be used to prepare pharmaceutical composition or
Preparation, described pharmaceutical composition or preparation are for preventing and/or treating eye disease caused by crystalline lens lesion；
In another preferred example, compound shown in the Formulas I is I-1 compound:
In another preferred example, the eye disease is selected from the group: cataract, presbyopia, myopia, cortex is muddy,
The ocular complications that presbyopia nuclear hardening, diabetes cause.
In another preferred example, the cataract is selected from the group: congenital cataract obtains cataract.
It in another preferred example, include: (a) effectively controlling as the first active constituent in described pharmaceutical composition or preparation
The Formulas I compound represented for the treatment of amount or its optical isomer or its racemic modification or its solvate or its can pharmaceutically connect
The salt received or its prodrug；(b) pharmaceutically acceptable carrier；
Wherein, the content of the first active constituent is 0.001-99wt%, preferable 0.01-70wt%, more preferably 0.05-
40wt%'s, according to the total weight of composition.
In another preferred example, the dosage form of the Pharmaceutical composition or preparation is selected from: injection, takes orally external preparation
Preparation.
In another preferred example, the dosage form of the Pharmaceutical composition or preparation is eye-drops preparations, the eye-drops preparations
For eyedrops, emulsion, gel, ophthalmically acceptable cream, sustained-release micro-spheres, intraocular slow-released plant piece, medicinal slow-release medicine-membrane.
In another preferred example, the Pharmaceutical composition or preparation further include: (c) second active constituent, wherein described
The second active constituent be selected from the group: comprising containing in mushroom in wool lipoid substance, all rust leather hole Zoopagales or Aphyllophorales
Any compound for having, azole compounds, glucocorticoids compound, antibiotic, or combinations thereof.
In another preferred example, the content of second active constituent is 0.01-20wt%, preferably 5-
15wt%, according to the total weight of composition.
In another preferred example, when " second active constituent " is wool lipoid substance, concentration is preferably 10
~200mM, preferably 15~150mM, more preferably 20~50mM；Most preferably 20~30mM.
In another preferred example, the wool lipoid substance is selected from: lanosterol.
In another preferred example, the glucocorticoid compound is selected from the group: dexamethasone, hydrocortisone or
A combination thereof.
In another preferred example, the antibiotic is selected from the group: tobramycin, gentamicin sulphate, aureomycin, chlorine are mould
Element, or combinations thereof.
In another preferred example, the azole compounds are selected from econazole, Isoconazole, bifonazole, clotrimazole, A Li
Piperazine azoles, ketoconazole, Fluconazole, phenylimidazole, Miconazole, ciproconazole, Triadimenol, Tebuconazole, propiconazole, or combinations thereof.
Second aspect of the present invention provides a kind of method of the improvement crystalline lens transparency of external non-therapeutic, it include: by
Crystalline lens and compound shown in Formulas I or its optical isomer or its racemic modification or its solvate or its can pharmaceutically connect
The salt received or its prodrug thereof are transparent so as to improve (or raising) crystalline lens, wherein this hair of compound described in the Formulas I
Described in bright first aspect.
Third aspect present invention provides a kind of method prevented and/or treat eye disease caused by crystalline lens lesion, gives
Give required object compound shown in Formulas I or its optical isomer or its racemic modification or its is molten as described in the first aspect of the invention
Agent compound or its pharmaceutically acceptable salt or its prodrug.
In another preferred example, the object behaviour and non-human mammal.Typically, the non-human mammal
Including (but being not limited to): pet (such as dog, cat), domestic animal (such as ox, sheep, horse, pig), various zoo animals (panda, elephant)
Deng.
In another preferred example, the object further includes other animals in addition to people and non-human mammal, such as the non-food in one's mouth
Newborn animal.
It should be understood that above-mentioned each technical characteristic of the invention and having in below (eg embodiment) within the scope of the present invention
It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, exist
This no longer tires out one by one states.
Detailed description of the invention
Fig. 1 is the form of the upper light source of rat lens after cataract modeling success in 1 group of the embodiment of the present invention.
Fig. 2 is the form of the lower light source of rat lens after cataract modeling success in 1 group of the embodiment of the present invention.
Fig. 3 is the form of the upper light source of rat lens after cataract modeling success in 1 group of comparative example of the present invention.
Fig. 4 is the form of the lower light source of rat lens after cataract modeling success in 1 group of comparative example of the present invention.
Fig. 5 is the form of the upper light source of rat lens after 1 group of experiment of the embodiment of the present invention.
Fig. 6 is the form of the lower light source of rat lens after 1 group of experiment of the embodiment of the present invention.
Fig. 7 is the form of the upper light source of rat lens after 1 group of experiment of comparative example of the present invention.
Fig. 8 is the form of the lower light source of rat lens after 1 group of experiment of comparative example of the present invention.
Specific embodiment
The present invention has unexpectedly discovered a kind of Inonotus obliquus alcohol (Formulas I shownization by extensive and in-depth study for the first time
Close object) it can significantly prevent and/or treat eye disease caused by crystalline lens lesion.The present invention is the experimental results showed that shown in Formulas I
Compound is rapidly achieved eye disease effect caused by healing and prevention crystalline lens lesion with simple administration mode.Based on
Upper discovery, inventor complete the present invention.
Term
As used herein, term "comprising", " comprising ", " containing " are used interchangeably, and include not only closed definition, also wrap
Include semiclosed and open definition.In other words, the term include " by ... constitute ", " substantially by ... constitute ".
Inonotus obliquus alcohol
Present invention firstly discovers that purposes of the Inonotus obliquus alcohol (compound shown in Formulas I) in terms of curing eye diseases, the birch
Brown hole mykol (compound shown in Formulas I) is used to prepare pharmaceutical composition or preparation, and described pharmaceutical composition or preparation are for preventing
And/or eye disease caused by treatment crystalline lens lesion.
As used herein, term " the compounds of this invention ", " compound shown in Formulas I " and " Inonotus obliquus alcohol " is interchangeable makes
With, refer to formula Inonotus obliquus alcohol (compound shown in Formulas I) or its optical isomer or its racemic modification or its solvate or its
Pharmaceutically acceptable salt or its prodrug.It should be understood that the term further includes the mixture of said components, the compound shown in Formulas I
In, if there is asymmetric carbon atom, then asymmetric carbon atom can be R configuration, or S configuration, or both mixture.
The structure of compound shown in Formulas I is as follows:
Formulas I (Inonotus obliquus alcohol, Inotodiol)
In a preference of the invention, compound shown in the Formulas I is I-1 compound:
In the present invention, term " pharmaceutically acceptable salt " refers to that the compounds of this invention and acid or alkali are formed by suitable use
Make the salt of drug.Pharmaceutically acceptable salt includes inorganic salts and organic salt.A kind of preferred salt is the compounds of this invention and acid
The salt of formation.The acid for suitably forming salt includes but is not limited to: hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid etc. are inorganic
Acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid,
Picric acid, methanesulfonic acid, benzene methanesulfonic acid, the organic acids such as benzene sulfonic acid；And the acidic amino acids such as aspartic acid, glutamic acid.It is a kind of excellent
The salt of choosing is the salt that the compounds of this invention and alkali are formed.The acid for suitably forming salt includes but is not limited to: sodium hydroxide, hydroxide
The inorganic bases such as potassium, sodium carbonate, sodium bicarbonate, sodium phosphate, the organic bases such as ammonium hydroxide, triethylamine, diethylamine.
In the present invention, term " prodrug " is also referred to as pro-drug, prodrug, forerunner's drug etc., refers to by organism
Just with the compound of pharmacological action after interior conversion.Pro-drug itself is very low without bioactivity or activity, by internal generation
Become active substance after thanking, the purpose of this process is to increase the bioavilability of drug, reinforces targeting, reduce medicine
The Side effect of object.In the present invention, the prodrug of compound shown in Formulas I is metabolizable (representative at compound shown in Formulas I
Such as Inonotus obliquus alcohol).
Method system well known to those skilled in the art in the prior art can be used in compound shown in Formulas I of the invention
It is standby, the response parameter of each step is not particularly limited.It is obtained in addition, the compound of the present invention can also be bought by market.
Typically, extracting and developing and the purifying preparation gained from Inonotus obliquus of compound shown in Formulas I of the present invention.
In the present invention, inventor carries out pharmacokinetic to Inonotus obliquus alcohol, as a result, it has been found that, Inonotus obliquus alcohol can
It is obviously prolonged the half-life period of compound shown in Formulas I, the aggregate concentration in eye is improved, extends the residence time of eye, raising pair
The therapeutic effect of eye disease.
Purposes
Compound or its optical isomer or its racemic modification or its solvate shown in the above-mentioned Formulas I of the present invention or its
Pharmaceutically acceptable salt or its prodrug or its prodrug are used to prepare pharmaceutical composition or preparation, described pharmaceutical composition or system
Agent is for preventing and/or treating eye disease caused by crystalline lens lesion.
In another preferred example, the eye disease (but being not limited to): cataract, presbyopia, myopia, cortex are mixed
The ocular complications that turbid, presbyopia nuclear hardening, diabetes cause.
As used herein, term " cataract " refer to show to cause on lenticular surface and/or inside it is muddy or not
It is transparent, or the disease or illness of crystalline lens swelling are induced, including congenital cataract and acquisition cataract.It is representative,
The cataract is to include but is not limited to: age-related cataract, diabetic cataract, it is relevant to operation it is white in
Cataract caused by cataract, infection caused by cataract, genetic disease caused by barrier, radioactive ray irradiate or drug cause
Cataract.
As used herein, term " presbyopia " refers to that the crystalline lens of eyes loses its visual state flexible, thus difficult
To focus on closer object.
Typically, eye disease caused by the crystalline lens lesion does not include conjunctivitis, because of pathogen (such as bacterium, disease
The microorganisms such as poison) caused by eye infection or inflammation of eye section.
As used herein, term " prevention " refer to before eye disease apply therapeutically effective amount Formulas I shown in compound or its
Optical isomer or its racemic modification or its solvate or its pharmaceutically acceptable salt or its prodrug or its prodrug, from
And the eye disease is prevented, time of origin postpone or still occur, but compare do not apply compound shown in Formulas I or
Its optical isomer or its racemic modification or its solvate or its pharmaceutically acceptable salt or its prodrug or its prodrug
Degree mitigate.As used herein, term " treatment ", refer to application therapeutically effective amount Formulas I shown in compound or its optical siomerism
Body or its racemic modification or its solvate or its pharmaceutically acceptable salt or its prodrug or its prodrug, thus reduce,
Mitigate or slow down eye disease, obstruction and illness progress or development.In another embodiment, " treatment " refers to mitigation, slows down
The process of eye disease, obstruction and illness, or improve one or more S or Ss of eye disease, obstruction and illness.
" prevention " and " treatment " of the present invention include delaying and terminating the progress of disease, or eliminate crystalline lens lesion and draw
The eye disease risen, does not need 100% inhibition, elimination and reverse.In some embodiments, and there is no of the present invention
When compound and composition described in Formulas I or preparation (for example, be not exposed to the compound described in formula I and composition or
In the matched control subject of preparation biology or sample) level observed compares, compound described in Formulas I of the present invention and
Eye disease caused by crystalline lens lesion (such as cataract) is mitigated, prevented, inhibited and/or reversed for example by composition or preparation
At least about 10%, at least about 30%, at least about 50% or at least about 80%.
Pharmaceutical composition or preparation and method of administration
Since the compounds of this invention has eye disease caused by excellent prevention and/or treatment crystalline lens lesion,
The pharmaceutical composition or preparation of active constituent containing the compounds of this invention can be used for preventing and/or treating crystalline lens lesion and cause
Eye disease, such as cataract.It include: the effective treatment of (a) as the first active constituent in described pharmaceutical composition or preparation
The Formulas I compound represented of amount or its optical isomer or its racemic modification or its solvate or its is pharmaceutically acceptable
Salt or its prodrug；(b) pharmaceutically acceptable carrier.
Wherein, the content of the first active constituent is 0.001-99wt%, preferable 0.01-70wt%, more preferably 0.05-
40wt%'s, according to the total weight of composition.
In another preferred example, the Pharmaceutical composition or preparation further include: (c) second active constituent, wherein described
The second active constituent be selected from the group: comprising containing in mushroom in wool lipoid substance, all rust leather hole Zoopagales or Aphyllophorales
Any compound for having, azole compounds, glucocorticoids compound, antibiotic, or combinations thereof.
In another preferred example, the content of second active constituent is 0.01-20wt%, preferably 5-
15wt%, according to the total weight of composition.
In another preferred example, when " second active constituent " is wool lipoid substance, concentration is preferably 10
~200mM, preferably 15~150mM, more preferably 20~50mM；Most preferably 20~30mM.
In another preferred example, the wool lipoid substance is selected from: lanosterol.
In another preferred example, the glucocorticoid compound is selected from the group: dexamethasone, hydrocortisone or
A combination thereof.
In another preferred example, the antibiotic is selected from the group: tobramycin, gentamicin sulphate, aureomycin, chlorine are mould
Element, or combinations thereof.
In another preferred example, the azole compounds are selected from econazole, Isoconazole, bifonazole, clotrimazole, A Li
Piperazine azoles, ketoconazole, Fluconazole, phenylimidazole, Miconazole, ciproconazole, Triadimenol, Tebuconazole, propiconazole, or combinations thereof.
As used herein, term " effective therapeutic dose " refers to and generates function or active and can be by people to people and/or animal
And/or the amount that animal is received.It will be apparent to an ordinarily skilled person in the art that " effective quantity " or " effective dose " can
Combine with the form of pharmaceutical composition, administration route, the auxiliary material of drug used, the severity of disease and with other drugs
Situations such as medication it is different and different.
Term " pharmaceutically acceptable carrier " refers to: one or more biocompatible solids, semisolid, liquid or gel
Filler, they are suitable for human body or animal uses and it is necessary to have enough purity and sufficiently low toxicity." compatibility " refers to
The active constituent of each component and drug in pharmaceutical composition and they between mutually admix, and significantly reduce drug effect.
It should be understood that in the present invention, the carrier is not particularly limited, material commonly used in the art can be selected, or use
Conventional method is made, or is commercially available from market.
Pharmaceutically acceptable carrier partial example has cellulose and its derivates (such as methylcellulose, ethyl cellulose, hydroxyl
Third methylcellulose, sodium carboxymethylcellulose etc.), gelatin, talcum powder, solid lubricant (such as stearic acid, magnesium stearate), sulfuric acid
Calcium, vegetable oil (such as soya-bean oil, sesame oil, peanut oil, olive oil), polyalcohol (such as propylene glycol, glycerol, mannitol, sorbierite
Deng), emulsifier (such as tween), wetting agent (such as lauryl sodium sulfate), buffer, chelating agent, thickener, pH adjusting agent, thoroughly
Skin promotor, colorant, flavoring agent, stabilizer, antioxidant, preservative, bacteriostatic agent, apirogen water etc..
Other than active pharmaceutical ingredient, liquid dosage form may include the inert diluent routinely used in this field, such as water or
Other solvents, solubilizer and emulsifier, for example, ethyl alcohol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-BDO,
Dimethylformamide and oil, especially cottonseed oil, peanut oil, maize germ, olive oil, castor oil and sesame oil or these objects
The mixture etc. of matter.
Other than these inert diluents, composition also may include auxiliary agent, such as wetting agent, emulsifier and suspending agent
In the present invention, the dosage form of pharmaceutical composition includes but is not limited to injection, external preparation, oral preparation.Generation
Table includes but is not limited to: tablet, injection, infusion solution, paste, gelling agent, solution, microballoon, film.
A kind of preferred dosage form is eye-drops preparations.It is representative, the eye-drops preparations be eyedrops, emulsion, gel,
Ophthalmically acceptable cream, sustained-release micro-spheres, intraocular slow-released plant piece, medicinal slow-release medicine-membrane.
The eye-drops preparations includes pharmaceutically acceptable pharmaceutical carrier, representative from including but not limited to: solvent
Or diluent, surfactant, thickener, osmotic pressure regulator, pH adjusting agent, bacteriostatic agent, chelating agent.
Solvent
(such as eye drops, eyedrops) use is solvent in eye-drops preparations or diluent includes aqueous solvent or nonaqueous solvents.
The aqueous solvent includes distilled water, physiological saline, water for injection etc.；Nonaqueous solvents used includes ethyl alcohol, propylene glycol, sweet
Oil, vegetable oil (such as castor oil, corn oil, injection soybean oil).
Surfactant
In eye-drops preparations, surfactant is selected from anionic surfactant, cationic surfactant, nonionic table
Face activating agent, chaotropic type (chaotropic) surfactant or combinations thereof.Wherein nonionic surfactant is selected from: tween,
Sapn, fatty glyceride, polyoxyethylene, Pluronic F68, or combinations thereof.General surfactant
Dosage (or content) be 0-2wt%, more preferably 0.1-1wt%.
Thickener
In eye-drops preparations, thickener can be used for improving object system viscosity, and object system is made to keep uniformly stable suspended state
Or milkiness state increases drug in the residence time of eye, to increase eye for effectively small by adding appropriate thickener
The absorption of ingredient.
In eye-drops preparations, thickener is preferably chitosan, hydroxypropyl methyl cellulose (HPMC), methylcellulose (MC),
With povidone (PVP), gelatin, sodium carboxymethylcellulose (CMC-Na) etc..Generally, the dosage (or content) of thickener be 0~
6wt%, preferably 0.1-5wt%.
Osmotic pressure regulator
Osmotic pressure regulator appropriate is added in ophthalmic preparations, makes the infiltration of the osmotic pressure human body ocular environment of eye-drops preparations
Press it is similar, to reduce stimulation to eye.Representativeness, common osmotic pressure regulator include but is not limited to acetic acid, second
Sour sodium, sodium bicarbonate.In general, the dosage (or content) of osmotic pressure regulator make eye-drops preparations be maintained at one it is isotonic or isotonic
In environment.
PH adjusting agent
PH adjusting agent appropriate is added in ophthalmic preparations, so that the pH value of eye-drops preparations is maintained at a proper range, with people
The pH of body ocular environment is similar, to reduce the stimulation to eye.Representativeness, common pH adjusting agent include but is not limited to
Sodium chloride, potassium chloride, glucose.In general, pH adjusting agent dosage (or content) makes the pH value of eye-drops preparations be maintained at 5-9.
Bacteriostatic agent
In eye-drops preparations, it is suitably added
The growth of bacterium in creme is killed or inhibited, prevents bacteria breed excessive, is detrimental to health.In the present invention,
Bacteriostatic agent is not particularly limited, and can be one of nipalgin alcohol, paraben esters or multiple combinations.It is representative, this
Bacteriostatic agent in invention is selected from the group: methylparaben, ethylparaben, propylben, or combinations thereof.
Chelating agent
In ophthalmic preparations, it is suitably added a certain amount of chelating agent, such as EDTA, the stability of preparation can be increased.In general, chela
The concentration range of mixture is 0~0.05wt%.
Composition or preparation method of application of the present invention is not particularly limited, and representative method of application includes (but simultaneously
It is not limited to): the modes such as local administration, oral, injection.
A kind of preferred method of application be the composition or preparation are carried out to topical ocular administration, including eyeball administration,
Eye mucosal drug delivery etc., it is representative that eyedrops, intraocular injection, eye Submucous injection, eye mucous membrane film mode is such as added dropwise.
Pharmaceutical preparation should match with administration mode.Medicament of the present invention can also be used together (packet with other synergistic treatment agent
Before including, among or use later).It is the medicament administration by safe and effective amount in required when using pharmaceutical composition or preparation
Object (such as people or non-human mammal), the safe and effective amount typically at least about 10 micrograms/kg body weight, and most of
In the case of no more than about 8 mg/kg weight, preferably the dosage is about 1 mg/kg body of about 10 micrograms/kg body weight-
Weight.Certainly, specific dosage is also contemplated that the factors such as administration route, patient health situation, these are all skilled practitioners technical ability ranges
Within.
The method of the improvement crystalline lens transparency of external non-therapeutic
The present invention provides a kind of methods of the improvement crystalline lens transparency of external non-therapeutic, by crystalline lens and Formulas I institute
Show compound or its optical isomer or its racemic modification or its solvate or its pharmaceutically acceptable salt or its before
Medicine contact, it is transparent so as to improve (or raising) crystalline lens, wherein compound described in the Formulas I is as described herein.
The method of eye disease caused by prevention and/or treatment crystalline lens lesion
The present invention also provides a kind of method of eye disease caused by prevention and/or treatment crystalline lens lesion, this method
Including step, give required object apply compound shown in Formulas I of the present invention or its optical isomer or its racemic modification,
Or its solvate or its pharmaceutically acceptable salt or its prodrug.
In another preferred example, the object behaviour and non-human mammal.Typically, the non-human mammal
Including (but being not limited to): pet (such as dog, cat), domestic animal (such as ox, sheep, horse, pig), various zoo animals (panda, elephant,
Tiger) etc..
In another preferred example, the object further includes other animals in addition to people and non-human mammal, such as the non-food in one's mouth
Newborn animal.
Main advantages of the present invention include:
(a) present invention firstly discovers that compound shown in Formulas I can prevent and/or Prevention and/or treatment crystalline lens
Eye disease eye disease caused by lesion such as the prevention and treatment of cataract, and has significant therapeutic effect.
(b) compound shown in Formulas I of the invention has excellent safety, toxic side effect very little or almost non-toxic secondary work
With.
(c) metabolism of Inonotus obliquus alcohol vivo environment is slow, and bioavilability is high, suitable ocular administration (including eye drops),
The various ways administration such as oral, part.
(d) compound shown in Formulas I of the invention for the treatment to eye disease with good development and application prospects.
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part, or according to the normal condition proposed by manufacturer.Unless otherwise stated, otherwise percentage and number are calculated by weight.
Embodiment 1
Inonotus obliquus alcohol eye drop formulation:
Inonotus obliquus alcohol eye drop formulation in 1 embodiment 1 of table
Preparation method
10mg Tween-80 and 0.125g Inonotus obliquus alcohol is added sequentially in the PBS solution of 2mL, ultrasound to mixing
Uniformly, component A is made.4g hydroxypropyl-β-cyclodextrin is added in 5mL PBS solution again, component B is made.By component B points four
Secondary addition component A, ultrasound add 10mg EDTA-2Na, PBS solution are added to be settled to 10mL to being uniformly mixed.
Comparative example 1
Lanosterol eye drop formulation:
The structure of lanosterol is similar with the structure of Inonotus obliquus alcohol.
Lanosterol eye drop formulation in 2 comparative example of table
Preparation method
10mg Tween-80 and 0.125g lanosterol is added sequentially in the PBS solution of 2mL, ultrasound is equal to mixing
It is even, component A is made.4g hydroxypropyl-β-cyclodextrin is added in 5mL PBS solution again, component B is made.In four times by component B
Component A is added, ultrasound adds 10mg EDTA-2Na, PBS solution is added to be settled to 10mL to being uniformly mixed.
1 cataract therapy effect expedition of embodiment 1 and comparative example
Cataract modeling
Rat cataract model foundation.10-13 days after giving birth to Wistar rats are selected, male and female are unlimited, made with sodium selenite
Mould, every rat is according to 20 μm of ol/kg weight, in back neck subcutaneous injection.Sodium selenite is prepared with medical saline, is prepared
Room temperature is kept in dark place after 0.22 μm of film filtration sterilization of solution afterwards.I.e. eye, which can be observed, obvious caryogram after rat opens eyes
Cataract.
Cataract therapy effect expedition
By cataract rat model, 2 groups are divided into according to the right and left eyes of every rat, every group 8 corresponding eyeballs are brilliant
1 group of shape body, respectively example 1 group and comparative example, before experiment starts, two lenticular shapes of group rat eye are observed respectively
State, and take pictures, wherein the form of the lenticular upper light source of rat eye and lower light source is divided after example 1 group cataract modeling success
Not not as depicted in figs. 1 and 2；The shape of rat eye lenticular upper light source and lower light source after 1 group of cataract modeling success of comparative example
State difference is as shown in Figure 3 and Figure 4.Scoring of taking pictures after the crystalline lens taking-up of rat is 5 points
Every rat in example 1 group and 1 group of comparative example or so crystalline lens are separately immersed in Inonotus obliquus alcohol medicament for the eyes
It in water and same concentrations analogue lanosterol eyedrops, observing effect and scores after two weeks, wherein example 1 group is real
The form of the lenticular upper light source of rat eye and lower light source difference is as shown in Figure 5 and Figure 6 after testing；1 group of experiment of comparative example
After the form of the lenticular upper light source of rat eye and lower light source difference it is as shown in Figure 7 and Figure 8；Standards of grading are:
5 points-cataract core is full, the smooth of the edge, completely opaque；
4 points-cataract core center is full, disperse occurs in edge, completely opaque；
3 points-cataract Assessment of Nuclear Volume becomes smaller but unobvious, opaque area density declines；
2 points-cataract core is reduced significantly；
1 point-cataract core disappears, and cortex is transparent, and crystal restores normal.
As a result as follows:
3 embodiment 1 of table and comparative example 1 score to the therapeutic effect of cataract
| Group | Rat A | Rat B | Rat C | Rat D | Rat E | Rat F | Rat G | Rat H |
| Embodiment 1 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 |
| Comparative example 1 | 5 | 4 | 5 | 3 | 5 | 4 | 5 | 4 |
From table 3 it is observed that the Inonotus obliquus alcohol in the present invention is relative to analogue lanosterol with simple
Administration mode is rapidly achieved healing and prevents the effect of animal cataract.With better treatment cataract therapy effect.
Pharmacokinetics is investigated
Experimental method and result
10 week old or so SD rat is taken, male and female are unlimited, after intraperitoneal injection yellow Jackets anaesthetize and expand pupil, row eye glass
Glass chamber injects art, and all animal eyes inject identical type drug, and drug injection amount is 5 microlitres, every kind in each glass cavity
Pharmaceutical formulation animal subject quantity is 4, drug metabolic condition in postoperative 10 days detection aqueous humors.
Compared with the drug concentration initial value after rigid injection, lanosterol concentration has dropped 82% ± 14.7%, and birch is brown
Pore fungi determining alcohol has dropped 11% ± 2.3%.
All references mentioned in the present invention is incorporated herein by reference, independent just as each document
It is incorporated as with reference to such.In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art can
To make various changes or modifications to the present invention, such equivalent forms equally fall within model defined by the application the appended claims
It encloses.
Claims (10)
1. compound shown in a kind of Formulas I or its optical isomer or its racemic modification or its solvate or its pharmaceutically may be used
The purposes of the salt of receiving or its prodrug or its prodrug, which is characterized in that be used to prepare pharmaceutical composition or preparation, the drug
Composition or preparation are for preventing and/or treating eye disease caused by crystalline lens lesion；
2. purposes as described in claim 1, which is characterized in that compound shown in the Formulas I is I-1 compound:
3. purposes as described in claim 1, which is characterized in that the eye disease is selected from the group: cataract, presbyopia,
The ocular complications that myopia, cortex muddiness, presbyopia nuclear hardening, diabetes cause.
4. purposes as described in claim 1, which is characterized in that the cataract is selected from the group: congenital cataract, acquisition
Cataract.
5. purposes as described in claim 1, which is characterized in that include: (a) in described pharmaceutical composition or preparation as first
The Formulas I compound represented of effective therapeutic dose of active constituent or its optical isomer or its racemic modification or its solvation
Object or its pharmaceutically acceptable salt or its prodrug；(b) pharmaceutically acceptable carrier；
Wherein, the content of the first active constituent is 0.001-99wt%, preferable 0.01-70wt%, more preferably 0.05-
40wt%'s, according to the total weight of composition.
6. purposes as described in claim 1, which is characterized in that the dosage form of the Pharmaceutical composition or preparation is selected from: injection
Agent, external preparation, oral preparation.
7. purposes as described in claim 1, which is characterized in that the dosage form of the Pharmaceutical composition or preparation is ophthalmically acceptable system
Agent, the eye-drops preparations are eyedrops, emulsion, gel, ophthalmically acceptable cream, sustained-release micro-spheres, intraocular slow-released plant piece, medicinal slow releasing medicinal
Film.
8. purposes as described in claim 1, which is characterized in that the Pharmaceutical composition or preparation further include: (c) second is living
Property ingredient, wherein second active constituent is selected from the group: wool lipoid substance, all rust remove from office hole Zoopagales or Aphyllophorales
In comprising contain in mushroom any compound, azole compounds, glucocorticoids compound, antibiotic, or combinations thereof.
9. a kind of method of the improvement crystalline lens transparency of external non-therapeutic, which is characterized in that will change shown in crystalline lens and Formulas I
It closes object or its optical isomer or its racemic modification or its solvate or its pharmaceutically acceptable salt or its prodrug connects
Touching, it is transparent so as to improve (or raising) crystalline lens, wherein compound described in the Formulas I is as described in claim 1.
10. a kind of method of eye disease caused by prevention and/or treatment crystalline lens lesion, which is characterized in that right needed for giving
The compound as shown in Formulas I as described in claim 1 or its optical isomer or its racemic modification or its solvate or its medicine
Acceptable salt or its prodrug on.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711480659.1A CN109985051A (en) | 2017-12-29 | 2017-12-29 | The new application of Inonotus obliquus alcohol |
| PCT/CN2018/125075 WO2019129249A1 (en) | 2017-12-29 | 2018-12-28 | Triterpenoid-containing pharmaceutical composition and use thereof |
| CN201880084560.6A CN111526878A (en) | 2017-12-29 | 2018-12-28 | Pharmaceutical composition containing triterpenes and application thereof |
| US16/959,084 US20200384003A1 (en) | 2017-12-29 | 2018-12-28 | Triterpenoid-containing pharmaceutical composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711480659.1A CN109985051A (en) | 2017-12-29 | 2017-12-29 | The new application of Inonotus obliquus alcohol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109985051A true CN109985051A (en) | 2019-07-09 |
Family
ID=67109118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711480659.1A Withdrawn CN109985051A (en) | 2017-12-29 | 2017-12-29 | The new application of Inonotus obliquus alcohol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109985051A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671116A (en) * | 2021-07-30 | 2023-02-03 | 武汉大学 | Use of 25-hydroxylanosterol |
-
2017
- 2017-12-29 CN CN201711480659.1A patent/CN109985051A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671116A (en) * | 2021-07-30 | 2023-02-03 | 武汉大学 | Use of 25-hydroxylanosterol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018036522A1 (en) | Lanosterol compound ophthalmic preparation | |
| CN107569494A (en) | Treatment of macular edema eye drops with Difluprednate | |
| CN109985050A (en) | The new application of bolt bacterium acid | |
| CN116600785A (en) | Compositions, devices and methods for treating infection and/or inflammation of the nose, ear and other tissues | |
| JP2021073209A (en) | Ophthalmic compositions of rifamycins and uses thereof | |
| WO2022073446A1 (en) | Use of penehyclidine in treatment or prevention of vision-impairing eye diseases | |
| CN101130083B (en) | Ophthalmic composition, producing method and use of the same | |
| CN109985051A (en) | The new application of Inonotus obliquus alcohol | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| JP6820658B2 (en) | Compositions for use in the treatment of eye diseases with dipyridamole | |
| CN103976943B (en) | For treating or prevent the ketorolac tromethamine compositions of ocular pain | |
| CN109985052A (en) | The new application of triterpene compound | |
| WO2018036523A1 (en) | Azole compound ophthalmic preparation | |
| EP4052694A1 (en) | Eye drop composition for preventing or treating eye disease | |
| CN109985071A (en) | The new application of Inonotus obliquus extract | |
| US9254289B2 (en) | Methods for treating eye disorders using dipyridamole | |
| CN112891326A (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| WO2022092209A1 (en) | Ocular-tension-increasing agent capable of being deprived of drug activity by temperature control | |
| US20120028947A1 (en) | Ophthalmic Compositions | |
| EP4364722A1 (en) | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor | |
| CN107970211A (en) | Preoperative cornea flushing liquor, preparation method and applications | |
| CN116570558B (en) | Voriconazole ophthalmic nanometer slow-release composition and preparation method and application thereof | |
| CN115957217A (en) | Eye preparation, preparation method and application | |
| CN116473918A (en) | Brimonidine tartrate eye drops and preparation method thereof | |
| CN116509993A (en) | Medicine for preventing and treating retinopathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190709 |